Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs VERTAVIS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Treatment of mild to moderate Alzheimer's disease,Off-label: treatment of other dementias, myasthenia gravis
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Terminal elimination half-life is 39–58 hours (mean 49 hours), supporting once-daily dosing. Steady state is achieved after 7–10 days.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Primarily hydrolyzed by plasma esterases; minor hepatic metabolism via CYP450 enzymes.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Approximately 70% of the dose is excreted renally as unchanged drug and 30% via biliary/fecal routes as metabolites.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Volume of distribution is 0.4–0.6 L/kg (approx 30–50 L in adults), indicating distribution primarily into extracellular fluid.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
Oral bioavailability is approximately 50% (range 30–70%) with food reducing rate but not extent of absorption.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use is not recommended.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No data available.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Safety and efficacy not established; no recommended dose.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
No specific dose adjustment; use with caution due to potential increased sensitivity and comorbidities.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
No FDA black box warning.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Cardiovascular effects (bradycardia, syncope),Gastrointestinal effects (nausea, vomiting, diarrhea),Seizures,Weight loss
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Hypersensitivity to Vertavis or any component,History of severe cholinergic adverse effects
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Avoid grapefruit and grapefruit juice as they may increase ergotamine levels and risk of toxicity. Limit caffeine intake as it can exacerbate headache and interact with ergotamine. Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) if migraines are triggered by tyramine.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures below human clinical exposure at 400 mg/day. First trimester: high risk of major congenital malformations; second and third trimesters: risk of fetal growth restriction and fetal death.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Contraindicated during breastfeeding. No data on presence in human milk; however, animal studies show drug and metabolites are excreted in milk. M/P ratio not known. Due to potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 3 weeks after last dose.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
No dose adjustments recommended during pregnancy as the drug is contraindicated. If unintentionally exposed, discontinue immediately. Physiologic changes in pregnancy may alter drug pharmacokinetics (e.g., increased volume of distribution, increased hepatic clearance), but no specific dose adjustment has been studied in pregnant women.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Vertavis (a combination of phenobarbital, ergotamine, and belladonna alkaloids) is used for migraine and tension-type headaches. Monitor for signs of ergotism (numbness, cold extremities, muscle pain) due to ergotamine; avoid prolonged use. Phenobarbital is a controlled substance (C-IV) with abuse potential; monitor for sedation and dependence. Belladonna alkaloids cause anticholinergic effects (dry mouth, blurred vision, urinary retention). Taper dose to avoid withdrawal; avoid in patients with peripheral vascular disease, coronary artery disease, or glaucoma.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
Take Vertavis at the first sign of headache; do not exceed recommended dose.,Do not use more than 10 days per month to avoid medication-overuse headache and ergotamine toxicity.,Report symptoms of ergotism such as cold fingers or toes, numbness, tingling, or muscle pain immediately.,This medication may cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Avoid alcohol; it can increase sedation and ergotamine side effects.,Do not suddenly stop taking this medication; withdrawal may cause rebound headaches or seizures.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs VERTAVIS, answered by our medical review team.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. VERTAVIS is a Prostacyclin Vasodilator that works by Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and VERTAVIS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of VERTAVIS is: 5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and VERTAVIS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. VERTAVIS is classified as Category C. Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures bel. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.